Since our results in vivo indicated that COX-2 affects vGPCR angiogenicity (Fig 5) and tumorigenicity (Fig 6) and VEGF secretion is essential for tumor angiogenesis, we tested modulation of VEGF expression by COX-2 inhibitors in the tumors. This evidence concerns the gene VEGFA and neoplasm.